

Veryan to Participate in Major European Medtech Conference

27th March 2013 – Vascular stent specialist Veryan Medical will be participating in the forthcoming Investment In Innovation (IN³) conference in Dublin, to be held between the 16th and 18th April 2013. This partnering, investment and networking event is a well-established favourite with Europe's medtech community, bringing together venture capitalists, corporates and start-ups. This is the first time that IN³ is being held in Ireland, the home of Veryan's R&D facility.

This privately held, venture-funded company, formed through a spin-out from Imperial College, London, has designed and patented a unique technology which creates a self-expanding nitinol (nickel-titanium alloy) stent with a three dimensional (3D) helical geometry; BioMimics 3D. This configuration mimics the actual shape of the human vascular system, encouraging a more natural 'swirling' pattern of blood flow in the 3D stented vessel than is observed in vessels treated with a conventional straight stent. Veryan has demonstrated in a standard preclinical in vivo model that swirling flow promoted by the use of a 3D stent significantly inhibits intimal hyperplasia that can lead to restenosis.

The 3D shape also helps improve the stent's biomechanical performance, increasing the stented segment's ability to withstand the compression, extension and flexion forces in the lower leg, which can lead to stent fracture, particularly in long obstructive or occlusive atherosclerotic lesions.


Veryan has developed its own peripheral vascular stent, BioMimics 3D, based on this patented technology. Following extensive bench, preclinical and clinical testing, the BioMimics 3D stent system obtained CE Mark approval for use in the treatment of the superficial femoral and proximal popliteal (femoropopliteal) arteries of the leg in November 2012.

Veryan is currently evaluating strategic opportunities for commercialisation of BioMimics 3D in Europe and other global markets which recognise the CE Mark, alongside a developmental pathway aimed at the US market. Femoropopliteal stenting is currently estimated to be worth USD 600 million, with a growth driven by an ageing population and increasingly sedentary lifestyles.

Veryan's patented technology can be applied to any laser-cut nitinol tube stent (which represents the majority of femoropopliteal stents used) on a cost neutral basis. Using Veryan's 3D stent technology would give manufacturers the opportunity to access potential improvements in blood flow, vascular healing response and biomechanical performance. Looking further ahead, preclinical studies have suggested that the technology could also be successfully applied to balloon-expandable stents.

The total global market for the endovascular treatment of peripheral arterial disease (PAD) is currently estimated at USD 2.5 billion and growing at a significant rate. The market is, however, highly competitive, with effective product differentiation being a key driver of market share. Veryan's dual business development strategy therefore offers a unique value proposition.

To request a meeting with Veryan representatives at IN³ please contact Chas Taylor on +44 1403 258984 or chas.taylor@veryanmed.com.



-Ends-

Media contact:

Richard Kenyon
richard@rkpr.co.uk
+44 7831 569940

About Veryan

Veryan is developing innovative solutions to improve the performance of vascular stents using the principles of biomimicry. Veryan's BioMimics 3D™ stent technology involves adapting traditional straight stent designs to a three-dimensional helical shape, which more closely mimics the natural geometry of the human vascular system. BioMimics 3D technology is designed to enhance clinical performance by improving flow conditions in, and bio-mechanical performance of, stented vessels.

Pre-clinical studies have shown that BioMimics 3D stent technology may significantly reduce restenosis (the narrowing of stented arterial segments) and confer significant mechanical benefits: the BioMimics 3D stent is more flexible, kink and fracture resistant than conventional counterparts.

To date, Veryan has received venture investments totalling GBP 17.7 million from Imperial Innovations, Seroba Kernal, Oxford Gateway, Nikko Principal and NESTA.

CAUTION: The BioMimics 3D stent is not available for sale or investigational use in the United States.

For further information, please visit: www.veryanmed.com